Sales of biotechnology-produced drugs have grown about twice as fast in the past ten years, both worldwide and in Germany, as they have with non-organic medicines. Although the focus is still on the treatment of cancer and autoimmune diseases in the biopharmaceuticals currently available on the market, there is also a gradual expansion to other indications. This increases the chances of treatment for previously unsatisfactorily treatable, serious illnesses. The market entry of biosimilars will also allow wider access to biological treatment options for more patients. In addition, there are also novel therapeutic technologies and dosage forms in the research pipelines, which nourishes hopes for further therapy advances.
Download the "Biologische Arzneimittel: Mehr Therapiechancen für Patienten" PDF or the images in PPT.